E Ghanem

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications

Corrigendum to "Targeting prohibitin with small molecules unravels a common signaling pathway for melanogenesis and apoptosis in melanoma cells" [Eur. J. Med. Chem. 155 (2018) 880].

Corrigendum to "Targeting prohibitin with small molecules unravels a common signaling pathway for melanogenesis and apoptosis in melanoma cells" [Eur. J. Med. Chem. 155 (2018) 880].

Journal: European journal of medicinal chemistry
Published: December 14, 2025

Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.

Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.

Journal: Oncotarget
Published: June 03, 2024

Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.

Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.

Journal: The Journal of clinical investigation
Published: May 01, 2024

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

Journal: The Journal of clinical investigation
Published: April 15, 2024

Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers 2020, 12, 512.

Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers 2020, 12, 512.

Journal: Cancers
Published: April 07, 2024

Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093.

Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093.

Journal: Cancers
Published: October 25, 2023

Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies.

Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies.

Journal: Cells
Published: May 10, 2023

Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.

Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.

Journal: Cancers
Published: March 03, 2023

The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma.

The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma.

Journal: Frontiers in medicine
Published: January 23, 2023

Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance.

Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance.

Journal: Cells
Published: October 20, 2022

Understanding the Radiobiological Mechanisms Induced by 177Lu-DOTATATE in Comparison to External Beam Radiation Therapy.

Understanding the Radiobiological Mechanisms Induced by 177Lu-DOTATATE in Comparison to External Beam Radiation Therapy.

Journal: International journal of molecular sciences
Published: August 22, 2022

Bufalin for an innovative therapeutic approach against cancer.

Bufalin for an innovative therapeutic approach against cancer.

Journal: Pharmacological research
Published: July 05, 2022
Showing 1-12 of 32

Last Updated: 09/26/2026